AliX

NovAliX is a leading drug discovery contract research organization (CRO) based in Strasbourg, France, specializing in structural biology, biophysics, and medicinal chemistry. Formed through the merger of AliX and Bio-Xtal, the company provides comprehensive services to pharmaceutical and biotechnology partners, leveraging advanced technologies such as cryo-electron microscopy (cryo-EM), X-ray crystallography, and DNA-encoded libraries (DEL). NovAliX focuses on accelerating the discovery of novel therapeutic candidates through a deep understanding of protein-ligand interactions and structural insights. The company supports a wide range of therapeutic areas, including oncology and infectious diseases, by offering tailored research solutions from target validation to lead optimization. Its integrated approach combines high-throughput screening with sophisticated biophysical characterization to address challenging drug targets.